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On the outside looking in: redefining the role of
analytical chemistry in the biosciences
Dominic J. Hare*ab and Elizabeth J. New*c
Biomedical research has moved on from the study of the structure of organs, cells and organelles.
Today, the key questions that must be addressed to understand the body in health and disease are
related to fundamental biochemistry: the distribution and speciation of chemicals, the regulation of
chemical reactions, and the control of chemical environments. To see advances in this field, it is
essential for analytical chemists to actively engage in this process, from beginning to end. In this Feature
Article, we review the progress that has been made towards gaining an understanding of the chemistry of
the body, while commenting on the intrinsic disconnect between new innovations in the field of analytical
chemistry and practical application within the biosciences. We identify the challenges that prevent
chemists from making a greater impact in this field, and highlight key steps for moving forward.
Introduction
In Theodore L. Brown’s seminal text, first published in 1977 and
now in its 12th edition,1 chemistry was described as the ‘central
science’, and nowhere is this more true than the biosciences.
Every cellular function, from mitotic division, to energy produc-
tion, and to eventual programmed cell death, is the result of a
chemical reaction, and the same can be said with respect to
the initiation of disease. Six of the past ten Nobel Prizes for
Chemistry are directly related to the biosciences, with the
remainder all having some relevant application to that discipline.
One need only look at some of the most significant advances in
biology in the past few years, such as the application of the
CRISPR/Cas system for gene editing2 or the CLARITY approach
visualisation of structure and protein distribution in intact
systems,3 to recognise the impact that innovative application
of chemistry can have within the biosciences.
Importantly, current challenges in biological research are
centred on the identification and quantification of chemical
analytes: from small molecules (such as signalling molecules,
drug metabolites or metal ions) to proteins and subcellular
structures. This is therefore an ideal context in which to apply
to concepts and techniques of analytical chemistry, whether by
adaptation of techniques in other applications, or through the
development of bespoke analytical solutions for the biological
context. While there are numerous biological analytes of interest,
the challenges and opportunities bear many common features.
As a result, this Feature Article will focus primarily on metal and
metalloprotein analytes by way of example, but the concepts
discussed here can be readily applied to any biological analyte.
Broadly speaking, analytical solutions can be divided into
(1) technologies – the development and adaptation of spectrometric
and spectroscopic instrumentation to gain information about the
chemical content of a biological system, and (2) reagents –
chemicals that react selectively with species of interest, enabling
their specific detection from within the complex environment of
the body. In this Feature Article, we focus primarily on various
mass spectrometric techniques as examples of technologies,
and on selective fluorescent probes as prototypical reagents,
designed for use with various technologies such as confocal
microscopy and flow cytometry. However, analytical chemistry
is multifaceted, and it is more than likely that specialists in
alternative techniques, such as vibrational or nuclear magnetic
resonance spectroscopy, would present a similar viewpoint from
their area of expertise.
Recent years have seen the development of a number of
analytical tools spanning the electromagnetic spectrum – from
X-ray spectroscopy to NMR spectroscopy. Some techniques, such
as mass spectrometry, can provide detail to the level of the atomic
nucleus, distinguishing isotopes, while others are able to report
on the macromolecular: synchrotron X-ray crystallography, for
example, can provide protein structures. Such techniques have
been extensively reviewed elsewhere.4,5 Here, we consider the
breadth of analytical chemistry’s role in the biosciences from the
perspective of the analyte (Fig. 1), as opposed to the suite of
techniques available. By grouping the analytical techniques in
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this way, it is clear that each biological question can be answered
by multiple techniques. Furthermore, since each technique has
inherent advantages and disadvantages, these approaches are
therefore complementary to one another. There is therefore
much benefit in applying more than one analytical approach to
a single investigation, to answer questions that no single techni-
que can achieve on its own. For example, an understanding of the
metal homeostasis of a cell requires understanding of its oxida-
tion state and coordination environment, which can be probed
by fluorescence microscopy or synchrotron X-ray fluorescence
techniques; total metal levels, which can be studied by mass
spectrometry methods; and the metalloprotein pool, which can
be investigated using immunostaining.6 Similarly, understanding
a protein’s role cannot be achieved by MS analysis alone; bio-
informatics is essential for sequencing the protein fromMS data,
X-ray crystallography and nuclear magnetic resonance are
indispensable tools for determining macromolecular structure,
and microscopy plays an important role in determining in vivo
distribution.
Analytical biochemistry: a dynamic and
evolving field
Observing the biochemistry of the cell is itself dependent on
our ability to manipulate chemical environments within a
biological system to instigate a measurable response. Analytical
biochemistry is applied in every biological research paradigm
in some way, shape or form; two of the three most cited papers
of all time7 report analytical chemistry techniques to study
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biological systems.8,9 Most mainstream applications are so
routine that an understanding of the fundamental principles
of these resources is not expected of the typical biologist. This
observation is not intended to undermine the ability of mem-
bers of the biosciences community; rather, it is testament to the
successful translation of what would once have been considered
complex and labour-intensive protocols into ‘plug-and-play’ devices
or simplified ‘recipes’, allowing biomedical researchers to instead
dedicate their own time and eﬀorts to delivering essential clinical
outcomes.
The number of scientists working at the interface of biology
and chemistry has exponentially increased in the past few
decades. Multidisciplinary science drives almost all innovation
in medical research, though there is often a significant delay
between the conception of an idea and its translation to pro-
viding answers for biological questions. This is perhaps best
exemplified in the interaction between chemistry and biology
in the development of new drugs. A potential drug must be
modelled, synthesised and purified by medicinal chemists,
tested for safety and eﬃcacy in animal models by biologists,
and translated to the clinic by medical professionals. This whole
process is a long, costly, and low-yielding, endeavour. A 2003
study estimated that a single new therapy takes, on average,
15 years and $US800 million to come to market.10 While this can
be somewhat attributed to the safeguards in place to ensure
adverse eﬀects are identified, which is a process that cannot be
rushed, the complexities of the process highlight the heavy
dependence on communication between each member of the
intellectual production line.
This concept is equally important in the translation of new
analytical chemistry approaches to pertinent biological questions,
although in this field, where studies are performed on model
systems rather than humans, many of the regulatory hurdles can
be avoided. While cross-collaboration is more common than ever,
there still exists something of a void between those at the cutting-
edge of each discipline, which often restricts the immediate
uptake of novel advances by those who would most benefit by
their application. The tools that have become so integral for
studying biochemistry themselves have a long history of develop-
ment and applications driven by innovation and need. In the
context of this Feature Article, we have focused onmicroscopy and
its evolution from a technique used specifically for visualising
structure to a broader term describing multiple techniques
used for assessing complex chemical interactions at the nano-
scale; and mass spectrometry (MS), which recently celebrated its
centenary11 and has been a mainstay of the chemical laboratory
since its commercialisation in the 1930s.12 As shown in Fig. 2,
each technological milestone reached is typically followed by the
introduction of new applications relevant to the bioscience,
though usually this occurs after some lag time. Microscopy and
MS represent only two subdisciplines of analytical chemistry:
similar progressive advances can be described for almost every
analytical instrument in the modern laboratory, from spectro-
scopy to chromatography (itself a driver of advances in MS
technology). As a general statement, in the modern era, better
communication and collaboration between chemists and
biologists has significantly reduced the gap between technological
innovation and practical biological research.
In this Feature Article, we discuss the progress made in further
shifting the ‘central’ science towards biology, with an emphasis
on our areas of expertise (mass spectrometry (MS), metal analysis
and fluorescence sensing). While focusing primarily on our
own areas of research interest, we intend this Feature Article to
be read with an open mind regarding the wider impacts that
analytical chemistry can have on the biological sciences. We
outline the steps needed to facilitate the rapid integration of
chemistry into both fundamental biochemistry and medical
research, and comment on the barriers that still hamper the
alignment of two rapidly moving, and sometimes divergent,
areas of science.
A potential diﬀerence: integrating
analytical chemistry into the
biosciences
In this Feature Article, our working definition of analytical
chemistry is the identification and/or quantification of chemical
species. Analytical chemistry played a key role in the derivation
of the fundamental laws of chemistry in the time of Lavoisier,15
and has seen enormous advances over the subsequent two
centuries. Modern analytical chemistry is sometimes referred
Fig. 2 Selected technological (blue) and application (red) milestones in the
development of microscopy (a; adapted from ref. 13) and mass spectro-
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to as ‘analytics’, a term designed to encompass not only the
measurement and quantification of a sample, but also the
increasingly complex data analysis techniques used to identify
relationships in complex mixtures, which is particularly perti-
nent in the biosciences.16 Analytical chemistry techniques
continue to be central to numerous fields, from archeology17
to environmental monitoring18 to the pharmaceutical industry,19
and analytical skills remain a key graduate attribute for
tertiary chemistry students: British chemistry graduates sur-
veyed 2.5 years after graduation identified analytical chemistry
as the most useful of all chemistry knowledge and skills gained
in their degree.20 Furthermore, a 2013 survey of over 4000
chemists employed in Europe found that the largest group
(17%) worked in analytical chemistry, across research and
development, analytical services and quality control sectors.21
However, despite the undisputed importance of analytical
chemistry in the workforce, analytical chemistry as an academic
discipline has lost favour in recent years, particularly at the
most competitive, research intensive universities. For example,
at only one of the eight Group of Eight (Go8) universities in
Australia is analytical chemistry listed as a research area on
the chemistry departmental website. Similarly, of the ten
highest-ranked chemistry departments in the UK Research
Assessment Exercise of 2014, only two list analytical chemistry
as a research strength. This apparent loss of popularity may be
due in part to analytical chemists rebranding themselves:
whether as environmental chemists, spectroscopists, or, in
the case of analytical chemistry for the biosciences, as chemical
biologists. In large part, such researchers lack the rigorous
training of analytical chemists of the past, and by failing to
align themselves with the broader analytical chemistry com-
munity, research outputs are not assessed for analytical rigour,
nor can they benefit from the wisdom of others engaged in
the field. To avoid unhelpful rifts and hierarchies, it is essential
that the research world acknowledge the historic and current
value of analytical chemistry, that traditional analytical chemists
realise the potential of their expertise in a range of sciences,
including the biosciences, and that those participating in
analytical chemistry research under other guises engage with
the analytical community.
The first application of analytical chemistry to the bio-
sciences can be traced back to histology, where chemical stains
for proteins and cellular features have been used for centuries.
After the invention of the light microscope and its first use in
the biosciences described by Marcello Malpighi in the 1600s,
scientists searched for new and better ways to visualise the
components of the cell, and in doing so harnessed the diversity
of cell biochemistry to selectively stain unique features, often
through simple trial and error. By the turn of the 20th century,
histochemical methods were a hotly debated topic amongst its
users, with dissensus often coming in the form of unsubtle
criticism in the literature. One example is Go¯mo¯ri’s unrest-
rained critique, published in 1936,22 of histochemical staining
of iron using the Perls and Turnbull protocols favoured by his
peers (and both still used frequently today23). Go¯mo¯ri’s assess-
ment of the methods available included statements such as
‘‘[t]herefore I see no reason why the Stoeltzner method,† using a
mixture of potassium ferro- and ferricyanide in order to ensure
demonstration of both ferric and ferrous compounds, should ever be
employed’’ and ‘‘[t]he alleged superiority of the Tirmann-Schmelzer
modification of Turnbull’s blue method‡ is based partly on
erroneous theoretical conceptions and partly on the misinterpreta-
tion of art[e]facts.’’ It is noteworthy that even relatively recent
studies using this stain still are somewhat unclear as to the
specificity of this approach to iron staining,24 particularly with
regard to its ability to diﬀerentiate iron oxidation states.
This example of the debate that surrounded early micro-
chemical analysis of the cell could be considered a prelude to
the diﬃculties faced by contemporary analytical chemists in
applying new techniques, as more is being asked than simply
information about the structure and appearance of the cell.
In the post-genomic era, snapshots of the chemical makeup of
an organelle provides infinitely more information with regard
to function, as modulating that function is the goal of those
seeking to both understand a biological mechanism or target
that function as a therapeutic intervention.
The ‘omic’ revolution (a phrase coined in 2000 by Glen Evans25)
has been driven by advances in analytical chemistry, from DNA
microarray technology to mass spectrometry. The major ‘omic’
sciences include, but are not limited to, proteomics26,27 (the
study of the protein component of the cell), transcriptomics28
(expression profiling, encompassing all RNA molecules), and
metabolomics29 (encompassing all breakdown products of
metabolic reactions). The latter has also been spun oﬀ into
numerous sub-omic sciences, recognising that measuring the
functional output of the cell requires targeted approaches, such
as lipidomics, which focuses on the multifaceted role of long-
chain hydrocarbons in the cell and often requires specialised
mass spectrometry approaches. Another important addition to
the ‘interactome’, a term intended to encompass all the complexi-
ties of chemical interactions within the cell30 is the discipline of
metallomics,31 which examines the entire metal complement
within a cell. Considering that as many a one-third of all proteins
contain a metal ion, and one half of all enzymes require a metal
to function,32 this relatively new ‘omic’ science (itself integrated
into proteomics to reflect the importance of metals and the
proteins they interact with33) shares with its peers an unwavering
reliance on advancing analytical technology to deliver results. In
their 2010 study of two simple microbial organisms with com-
paratively small proteomes, Cvetkovic et al.34 found that only 50%
of the metal-binding species they identified using a fusion of
traditional proteomic techniques and chromatographic separa-
tions designed to maintain metal–protein bonds could be asso-
ciated with known metalloproteins. Scaling this up to the human
genome, which encodes around 20000 proteins (not including
the innumerable post-translational modifications that would
influence metal binding), a large portion is therefore likely to
have interactions with metal ions that are either unknown or
poorly characterised.33
† A variant of the Turnbull method to produce ferrous ferricyanide.
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How analytical chemistry can solve
biological problems
‘Omic’ sciences are perhaps the best example of a successful
integration of chemistry and biology. There are two divergent
lines of enquiry with regard to ‘omic’ sciences and systems bio-
logy as a whole: (1) how can analytical chemistry be improved to
better answer key biological questions; and (2) are the right
questions being asked that take advantage of the tools at our
disposal? Desired outcomes are only achievable within the cap-
abilities of the approach used, which can either be a limitation or a
significant advantage. For instance, decoding of the human
genome relied upon a range of available gene annotationmethods,
the basis of which was first published in 197735 (referred to a
‘Sanger sequencing’), when the first draft sequence was released
in 2001.36 Since, the advent of high-throughput transcript
sequencing techniques, such as RNA-Seq,37 have vastly expanded
the information from which genome sequencing can provide.
In a sense, the field of genomics has stagnated, with papers
describing the fully sequenced DNA ‘library’ of an organism
no longer considered as impactful as they once were.38 Instead,
the arsenal of technologies for both chemical and in silico
analysis now available, commonly referred to as ‘next genera-
tion sequencing’,39 has dramatically changed the expectations
biologists have from analytical approaches, where biochemical
variation within a taxa has become of more importance. Loman
et al.40 described the current suite of available techniques
and platforms for genome and transcriptome sequencing as
‘‘an embarrassment of choice’’, noting that the rate of improve-
ments in sequencing technology is outpacing that of Moore’s law.
Without a doubt, biologists focusing on the genetic component
of the cell have driven incredibly fast development and applica-
tion of new analytical technology by asking questions that require
innovative answers from analytical chemists. It is unquestionable
that the pace of these advances was assisted by the heavy
financial support the Human Genome Project received,
($US3.8 billion by its completion in 2003, followed by an
additional $US8.5 billion in related research support), which
was estimated to have returned $US65 for every dollar spent.41
These (highly controversial) figures only refer to investment by the
US government; the total financial support given to the inter-
national consortium working on the Human Genome project
added even more capital to help drive analytical development.
For the fields that have grown from the Human Genome
Project, the lack of such a tangible goal as decoding the blue-
print for human life means innovation is not driven by the same
degree of financial support, and thus technological advances are
less frequent. This is not to say that older technology is obsolete
or no longer has a place; in several systems biology disciplines
this is far from the case. In 2002, Thierry Rabilloud described the
place of two-dimensional gel electrophoresis in proteomics as
‘‘old fashioned, but it still climbs up the mountains’’,42 predicting
that 2D gels will ‘‘blossom’’ again in the future. He was correct,
with 2D gel electrophoresis still routinely used, though most
advances in the method have come from improvements in
digital image analysis and amplification of detectable protein
signals (referred to in the discipline as diﬀerential imaging gel
electrophoresis, or DIGE),43 rather than improvements to the
physical separation of the proteins in a complex mixture by
electrophoresis. However, rapid advances in liquid chromato-
graphy (LC) over the past decade, driven by the miniaturisation
of separation devices and constantly improving integration of
these innovations with MS technology, have begun to oversha-
dow gel electrophoresis as the mainstay of proteomic technique.
Microchip assemblies, made possible through the advent of
advanced nanofabrication technology (which itself, no doubt,
lagged behind in terms of its uptake by the analytical chemistry
community), permit not only high resolution separation of
proteins, peptides and metabolites using minimal sample
volumes, but also allow for on-chip protein enrichment and
desalting in a high-throughput and often customisable format.44
These microchips, manufactured at a high quality standard, are
very reproducible, and interface well with many MS systems.
Thus, it begs the question, why haven’t chip and other LC-
based separation approaches completely usurped 2D gels in the
proteomics hierarchy more than they have? Unger et al.45 con-
sidered the contribution that multi-dimensional LC may have
as an alternative to 2D gels in 2000, concluding that develop-
ment ‘‘will probably last a decade until high-performance and
rugged systems will be on the market for the comprehensive on-line
approach.’’ This has been the case, though rather than sup-
planting 2D gel electrophoresis, LC-MS analysis has instead
complemented it. Workflows employing both techniques are
designed to capitalise on the advantages of both approaches,
reducing the chemical complexity of the sample and improving
sensitivity for the target analyte.46
An important consideration in the academic research world is,
however, cost. A fully stocked proteomics (or any other ‘omic’ lab
relying on MS technology) is a capital investment that in on par
with the highest expenses in medical research, such as magnetic
resonance imaging infrastructure. In the highly competitive
academic world, proteomics laboratories are usually built in a
modular fashion, as opposed to a major initial investment, with
new technology added as funds become available. Alternately,
universities and research institutes may invest in centralised
facilities, which are ideal for providing a service based on
standardised protocols, but rarely aﬀord time for method
development. Thus, outside of private industry, which can allow
the outlay but is reluctant to share new, potentially lucrative
developments in the public space, the application of new
innovation is often stymied by a lack of investment in future
technologies, which has perhaps kept older technologies like 2D
gel electrophoresis very much alive. Analytical manufacturers are
recognising this limitation, from both an altruistic and commer-
cial perspective: research breeds innovation, and much work at
the coalface of medical research is being undertaken at publicly
and philanthropically funded institutions.
Consider the advances in MS over the last decade, and the
fact they can be attributed to the tireless work of physicists
and engineers, and not the biologists who will ultimately use
the technology. We examined the yearly publication output for























































































Chem. Commun. This journal is©The Royal Society of Chemistry 2016
research: the inductively coupled plasma-mass spectrometer
(ICP-MS; launched commercially in 198347 and used for highly
sensitive analysis of metals and bioelements47); the matrix-assisted
laser desorption-time of flight-mass spectrometer (MALDI-TOF-MS;
launched in 199048 and for which John B. Fenn and Koichi Tanaka
were awarded the Nobel Prize for Chemistry in 2002 ‘‘for the
development of methods for identification and structure analyses of
biological macromolecules’’); and the Orbitrap MS (200549), a
super-high resolution Fourier transform mass analyser critical
for contemporary proteomics due to its unparalleled mass
accuracy (Fig. 3). Clearly, there is a significant lag in output
following the commercialisation of a new technology, and this
can be attributed to multiple factors. For ICP-MS, a system
initially designed for the geological and environmental sciences,
applications within biology were not realised until the mid-
2000s, and thus the technique has seen a steady growth since.
MALDI-TOF-MS, an immensely popular technology during the
chrysalis of proteomics as a discipline in its own right, showed
near-exponential growth until the mid-2000s, where it has since
plateaued, and the recent downturn in 2015 may be indicative of
the technology being superseded by improved technological
rivals, such as electrospray ionisation MS interfaces. The
Orbitrap design, proprietary to Thermo-Fisher Scientific, is an
interesting case study in itself, in that in-house published works
prior to its commercial release helped prepare the proteomics
community for the introduction of what would become a highly
sought-after and significant capital investment. This example is
an encouraging sign, where the manufacture of a MS system
clearly targeted to life scientists was marketed directly to the end
user, and has helped the measureable output of this technology
grow steadily over the following decade. These three technol-
ogies are just a few examples of high-end technology either
finding a niche in the life science space, or, as is the case with
ICP-MS, undergoing something of a renaissance once discovered
by biologists, which has in turn driven the development of new
variants specifically aimed at the life and medical research
communities (such as the triple quadrupole ICP-MS, designed
in part to meet the needs of high accuracy phosphorus analysis
for studying post-translational modifications in proteomics,50
whilst still having a foot firmly planted in the traditional ICP-MS
marketplace51). Even established biological MS approaches
themselves are able to find new life through diverse applications;
one need look no further than the explosion in interest of
imaging MS using MALDI, pioneered by Richard Caprioli in the
late 1990s52,53 and now being realised as a valuable clinical tool,
particularly in cancer research.54
Clearly, the most commonly asked questions of analytical
chemistry with respect to MS by the biosciences are: (1) how
much can I detect; (2) how fast can I do it; and (3) what flexibility
do I have with the type of analytes I’m interested in? As discussed
above, the chemical makeup of a cell has become the new
frontier for biologists, and sensitivity, throughput and versatility
drives both need and development of new technology. In their
colloquium on the history and future directions of MS technol-
ogy, engineers Maher et al.55 identified rapid analysis as being
the main direction MS research should be headed in. Beyond
this, and a question that is somewhat outside the scope of this
article yet still should be acknowledged is: what on Earth do I do
with all this data? Much like communication between analytical
chemists and biologists is key to delivering useful outcomes
relative to health research, giving biologists the power to sort
through data without suﬀering from the proverbial search for a
‘needle in a stack of needles’ is reliant on collaboration with
software developers and bioinformaticians. For a general over-
view and comprehensive list of relevant reading, we direct the
reader to the excellent review by Douglas Kell.56
New questions being asked by biologists are also giving a
new lease on life to well established analytical techniques.
Gas chromatography (GC), which is still widely used in high-
throughput settings around the world, is also finding new
applications for small molecule analysis, metabolomics and
within the pharmaceuticals industry.57 The excellent resolution,
peak capacity, sensitivity and potential for orthogonal chromato-
graphy coupled to highly sensitive MS makes GC an attractive
alternative to LC for certain analytes. One particular example of
interest is the application of GC-MS to lipidomics; fatty acids are
well suited to GC separation, can be derivatised en masse, and
have achievable detection limits in the femtogram range.58 As a
hyphenated technique, GC also benefits from the continuous
improvements made to MS technology, and the number and size
of GC-MS reference libraries (e.g. the National Institute of
Standards and Technology NIST 14 catalogue of nearly 250 000
unique compounds) is constantly growing.59
Not all as it seems: the importance of
correct data interpretation
Analytical chemistry has, without a doubt, contributed enormously
to studies of the biosciences. There is a potential, however, for
overinterpretation of experimental results, if investigators fail to
recognise the limitations of a technique. Importantly, it is essential
that in selecting an appropriate analytical technique to use,
researchers identify the specificity of the method, and interpret
data collected accordingly.
Fig. 3 Publication output in biological sciences for ICP-MS, MALDI-TOF-MS
and Orbitrap mass spectrometers from initial commercialisation (marked on
the x-axis) to 2015 (source: PubMed, accessed December 2015). ICP-MS and
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The specificity of an analytical technique refers to its distinction
between chemical species, whether diﬀerent chemical elements or
diﬀerent speciations of the same element. Mass spectrometry
methods, for example, can pinpoint exactly a single isotope,
but cannot report on the oxidation state or speciation of that
isotope. On the other hand, fluorescent probes can be selective for
individual oxidation states of metal ions,60,61 or metal coordina-
tion environments,62,63 but in some cases distinction of diﬀerent
analytes of similar properties is less straightforward.64,65
Persistent incorrect interpretation of specificity can severely
hamper research in a field. For example, in the field of cisplatin
chemotherapeutics, intracellular platinum levels are routinely
examined by bulk mass spectrometry techniques, which can
distinguish only total platinum levels, without sensitivity to
oxidation state and coordination environment. However, such
data is often reported as ‘intracellular cisplatin concentration’,66,67
suggesting that cisplatin remains intact within the cell, rather
than existing primarily as protein-bound adducts, as is now
understood.68
Speciation of chemicals within biological systems also
requires appreciation of the reactivity of the chemical in its
particular environment. This is true of metal ions, amongst
other species, for which the speciation strongly determines
cellular function or dysfunction. Not only is the oxidation state
of a redox-active metal crucial to appreciating its activity, but
the coordinating ligands also play a key role. Metal ions may be
tightly bound to proteins, eliciting activity at the protein active
site, but having little capacity to rapidly move within the cell,
or they may be loosely bound to cytoplasmic small molecules
or proteins. The latter pool, commonly termed the labile or
bioavailable pool, will be much more readily accessible for
exchange, and it is perturbations in the levels of the labile metal
pool that are believed to be involved in disease.6 In diﬀerent
circumstances, biological research questions may require study
of the protein bound metal pool, or the labile metal pool, or total
cellular metal, or some combination of the three. It is highly
likely, for example, that the total metal level remains constant in
response to a stimulus, while the protein-bound and labile pools
vary inversely, and measurement of the total metal pool alone
would fail to identify any changes. It is essential, therefore,
to recognise which analytical techniques can address each pool
(for example, laser ablation (LA)-ICP-MS or solution nebulisation
ICP-MS for the total metal pool; western blotting or immuno-
staining for protein-boundmetal; imaging using selective probes
for the labile metal pool), and where appropriate, to use multiple
techniques in parallel to best build a picture of metal distribu-
tion throughout the cell (see Fig. 4).
In addition to studying the speciation of analytes within the
cell, it is also essential to consider their localisation. Although
organelle structure is rarely the feature du jour of contemporary
cell biology, visualisation of organelle chemistry most certainly is.
Advanced fluorophores and super-resolution microscopy have
made assessing the chemical composition of the smallest cellular
features near routine. Biologists often search for colocalisation
of two fluorescent probes as evidence of biological interplay
between two variables, and while this may be indicative of some
kind of relationship between the analytes, image resolution
is not suﬃcient to definitively interpret apparent overlapping
structures as being colocalised.74
Localisation of a molecule or analyte within a cellular struc-
ture is still of great importance, though thorough and rigorous
interpretation of the data is required, including consideration of
all possible confounding factors. It is also essential to consider
the chemistry of the two (or more) analytes, when colocalisation
is intended to indicate a chemical relationship. Take the example
of imaging distinct pools of metals in biological cells.6 Metals
may be ubiquitous throughout the body, though, as demon-
strated by the emergence of metallomics andmetalloproteomics,
the function of a metal is driven by both its oxidation state and
the biological ligands to which it is bound. Imaging techniques,
such as LA-ICP-MS75,76 provides an extremely high level of
sensitivity and specificity, yet can only report on the total metal
content within a defined region (typically at the mm scale). In a
recent paper by Hare et al.,71 LA-ICP-MS was used to examine the
relationship between iron and dopamine, where the enzyme
tyrosine hydroxylase (the rate limiting step in dopamine synthesis)
was tagged with a gold nanoparticle labelled antibody. While this
study provided important data regarding the increased oxidative
Fig. 4 (a) Traditional Perls stain of liver showing non-heme iron deposits in
the characteristic blue hue of the Prussian blue pigment (Fe4[Fe(CN)6]3xH2O).
(b) 3,30-Diaminobenzidine (DAB) and cobalt-enhanced Perls stain (shown
here in liver tissue with neutral red counterstain) is reported to be more
sensitive than Perls staining alone.69,70 Neither method is quantitative,
though both are specific to non-heme iron, such as ferritin-bound Fe3+.
(c) LA-ICP-MS mapping of iron in the mouse substantia nigra pars reticulata
(adapted from Hare et al.;71 copyright 2014, Royal Society of Chemistry) is
both more sensitive and quantitative (with matrix-matched external calibra-
tion standards72,73), though image resolution is limited to the mm-scale (pixel
size depicted here is 25 mm2) and is sensitive to all chemical states of iron.
(d) Synchrotron-based X-ray fluorescence microscopy of the mouse brain
here shows marked iron deposition within the molecular cell layer of the
dentate gyrus, depicted here quantified against a thin standard film of iron and
at a spatial resolution of 4 mm2. Like LA-ICP-MS, XFM produces images of
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load imparted on dopaminergic neurons in Parkinson’s disease
by these two chemicals, it can only provide a partial picture of
the chemistry driving oxidative stress within these vulnerable
cells. Dopamine breakdown facilitated by iron results in the
formation of numerous neurotoxic metabolites,78 though this
mechanism relies upon the availability of ferrous (Fe2+) ions,
which are typically in (deliberate) short supply within the cyto-
plasm due to its potent redox activity. Therefore, conclusions
indicative of a confirmed relationship between iron and dopamine
within these neurons cannot be achieved through colocalisation
studies alone. Excess iron may be rendered redox-inactive by
ferritin,79 or the dopamine itself may be inaccessible to iron
through intracellular safe storage, such as in vessicles.80 Only
through further intervention, in this case the addition of a
potent neurotoxin known to elevate iron levels81 and measuring
response can we obtain additional evidence of correlation between
these two distinct chemicals, though this is far from providing
direct evidence of causation.
This highlights a significant shortcoming in colocalisation
analysis and the search for correlation: that of sensitivity. It is
plausible that significant colocalisation, and thereby indicators
of correlation are not detectable due to the extremely low
abundance of analytes that belies their biological significance.
Detection of the fluorophore, or even a low abundance biome-
tal, is dependent on the sensitivity of the analytical method
being used. This may be related to the fluorescent yield of the
fluorophore employed, the sensitivity of the detection techni-
que, or a combination of both factors. As we will discuss in
more detail, the development of next generation fluorescent
compounds for super-resolution microscopy is a fluid and
dynamic space, yet the uptake of these new sensors in the bio-
sciences, like the aforementioned example with mass spectro-
metry, is dependent on the users, not developers. A further
significant limitation in colocalisation analysis and the search
for correlation is that of sensitivity. It is plausible that signifi-
cant colocalisation, and thereby indicators of correlation are
not detectable due to the extremely low abundance of analytes
that belies their biological significance. This was illustrated in
our recent investigation of the colocalisation of biometals in
Caenorhabditis elegans, visualised using synchrotron X-ray fluores-
cence microscopy (XFM; Fig. 5).77 Since strontium is known to
substitute for calcium in biological systems,82 we might have
expected complete correlation of the two metals, but this was only
observed in the anterior gut region. The reason for this disparity
was one of sensitivity; XFM, though highly sensitive to calcium at
biological concentrations, was only able to discern strontium
distribution in areas of high abundance of this element.
Interpretation of ‘big data’ that is now a common output of
analytical chemistry, particularly in the ‘omic’ sciences, has
also brought about a need for input from biostatisticians and
bioinformatics experts. Chemometrics is not a new concept in
analytical chemistry, with multivariate analysis and artificial
neural networks for machine learning approaches used with great
success to improve analytical separation and classification of
complex mixtures.83 In the biosciences, this approach has become
integral in the sub-discipline of metabonomics, which diﬀers from
metabolomics in that it examines the multivariate eﬀects on a
system rather than focusing on specific metabolites.84 An overview
of chemometric applications to large datasets frommetabonomics,
in addition to genomics and proteomics studies can be found in
the review by Eriksson et al.85
Past, present and future: tools for
analytical chemistry in the biosciences
There is no shortage of chemical analysis techniques that are
available to the modern biologist. In the field of metal imaging
alone, a vast array of technologies, from mass spectrometry
to emission spectroscopy and fluorescent sensors, a biologist
has the freedom to pick and choose the appropriate technique
that is suited to the application he or she is using.86 The sole
limitation is accessibility, from either a practical perspective
(i.e. access to synchrotron-based radiation is restricted to
around 40 facilities worldwide); or a lack of ability to apply
what can be quite complex experimental protocols. Interface
scientists, who straddle both the development of analytical
techniques and their application to the biosciences are a
valuable commodity, as is embedding these scientists within
the biological research laboratories who will benefit most from
their expertise.
Fig. 5 (a) Simplified anatomical structure of Caenorhabditis elegans, with
the anterior intestine marked with dashed black box. (b) XFM mapping and
Li’s intensity correlation analysis on quantitative calcium and strontium
maps shows colocalisation and correlation (as according to Pearson’s rho,
Mander’s R and Li’s ICQ measures) in the anterior intestine, though a lack
of sensitivity for strontium, which is over 1000 times less abundant than
calcium, precludes any correlation analysis outside this area of high
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The primary role of the analytical chemist in this process,
then, is the development of new tools, or the application of
existing tools in new ways, to drive forward biological research.
In order to achieve greatest impact, it is essential to consider
the most valuable avenues for future research. This considera-
tion begs two questions: (1) is eﬀort being exerted towards the
most pertinent biological questions? (2) Are current tools being
utilised to best eﬀect in biological research?
In addressing the former, it is clear that much research
eﬀort is directed towards analytes that are easy to sense, rather
than being the most significant. According to Web of Science,
in 2015 alone there were over 110 publications describing new
fluorescent sensors for inorganic mercury ions, 35 of which cite
the endpoint application as measurement of exogenously added
mercury in cultured cells. It is unsurprising, however, that
mercury sensors are rarely used in detailed biological investiga-
tions, as endogenous total mercury levels in cells are orders of
magnitude below toxic concentrations.87
On the other hand, there is great value to be gained when
analytical tools are developed or modified in response to
scientific need. Amongst many other examples is the recently
commissioned Bionanoprobe at the Advanced Photon Source.
Synchrotron XFM has proved to be an invaluable analytical tool,
simultaneously providing multiple element maps.88 However,
recent studies suggested that results might be compromised by
conventional sample preparation, such as fixation, embedding
or dehydration.89 As a result, the Bionanoprobe was developed,
which enables cryogenic transfer and mounting of samples, to
avoid these sample preparation steps, thereby giving exquisite
information of trace elements in their native environments.90
Rather than just focusing on the ‘wants’ of the biologist,
however, it is important to appreciate that many analytical
techniques are rarely pushed to their extreme limits, and thus
the capabilities of modern equipment are often underutilised.
LA-ICP-MS is a prime example in the biosciences. First proposed
as a sample introduction technique for ICP-optical emission
spectroscopy in 198391 and then adapted for mass spectrometry
detection in 1985,92 LA-ICP-MS quickly developed a strong
following in the earth and environmental sciences,93 as it oﬀered
a viable alternative to the labour-intensive and often hazardous
sample preparation procedures that employed strong acids and
high-pressure microwave digestion. The first imaging application
of a biological sample was reported in 1994, where strontium and
calcium ratios in fish scales were mapped at 30 mm resolution,94
an impressive achievement considering contemporary LA-ICP-MS
mapping over 20 years hence is still only practical at the
1 mm level, and even then this requires specially designed
ablation chambers that have been developed only during the
past few years.95
Three main factors drive development of new analytical
equipment: improved sensitivity, ease of use, and reproducibility.
Sensitivity can be improved in a number of ways, from the
development of specialised analytical methods specific to a
target analyte to improvements of analytical hardware and
electronics that are responsible for the physical detection of a
molecule (in the case of MS) or characteristic emission profile
(for fluorophores). Simplifying the process is key to better
integrating technology into biological laboratories. For many
scientists, understanding the fundamental physics and chemistry
that dictate how an analytical system works is often irrelevant
to them, beyond the need to perform routine maintenance and
troubleshooting. This is not unreasonable, and the ‘black box’
paradigm of analytical instrumentation has forced manufacturers
to rethink both instrument front- (that is, the software controlling
them) and back-ends (the means by which data is extracted and
processed). There will always be room for improvement in this
area, though the advent of Electronic Laboratory Notebooks
(ELNs) and Laboratory Information Management Systems (LIMS),
many of which are open source,96 is encouraging. Proprietary
software and data management systems, such as Agilent
Technologies’ OpenLAB, are also finding a place within high
throughput laboratories and will soon permeate into the
research space. Remote access (including control of multiple
manufacturers’ systems) and multiple redundancies for data
storage forms a pipeline of information output that is acces-
sible to both users and stakeholders, and by centralising quality
control, maintenance requirements, data collection and analysis,
and report dissemination, these tools (both open source and
commercially produced) undoubtedly represent the future of
analytical chemistry with respect to its integration with medical
research and clinical sciences. However, reproducibility, where
analysis can be performed at the same standard in any equiva-
lent laboratory setting, is probably the most important factor in
expediting the uptake of analytical chemistry research by such
researchers.
The development of new analytical reagents, such as fluor-
escent probes, also follows these same lines. After identifying
pertinent analytes to target, typical probe design involves tethering
of a sensing element (designed to selectively interact with the
analyte) to a fluorophore, in such a way that the interaction of
analyte with the sensing group modulates fluorescence of the
fluorophore. Probe design tends to be centred around standard
classes of fluorophores.97 The primary challenge in sensing a new
analyte is therefore the identification and validation of sensing
elements that exhibit the required selectivity and sensitivity for
the particular application. However, photophysical and biological
properties of the probe must also be modulated to ensure best
eﬀect. A large class of zinc-sensing probes are based around the
fluorescein scaﬀold, exemplified by the first probe of its type,
Zinpyr-1 (Fig. 6).98 This class contains many examples of simple
modifications that give rise to improved photophysical and/or
biological behaviour. In general, zinc sensors are based on the
common, well-established sensing element containing pyridyl
groups or similar, and key modifications centre around the
remainder of the structure. Increased dynamic range gives rise
to lower detection limits and therefore greater sensitivity.99
Ratiometric probes, which signal changes in analyte through
changes in emission wavelength rather than emission intensity,
enable less ambiguous interpretation of data.100 Many bio-
logical questions are centred on specific organelles or cell types,
so the ability to target probes to specific regions of the cell or
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achieved by the incorporation of small molecule targeting
groups, the triphenylphosphonium moiety for mitochondrial
localisation,101 or by the use of short peptide sequences.103
Finally, a key challenge in probe design is the development of
more red-shifted emitters, which require less damaging, lower
energy excitation sources, and enable some degree of tissue
penetration. This can be achieved by the use of the related
xanthene-based fluorophore, rhodamine.102 In this domain,
replacement of the xanthene oxygen with a silicon atom gives
rise to near-IR emission, successfully utilised in preparation of
a Ca2+-selective sensor.104
When considering the potential application of fluorescent
sensors into the clinic, excitation and emission wavelengths
are key, with wavelengths of greater than 700 nm required for
suﬃcient tissue penetration.105 The development of new fluores-
cent scaﬀolds with such properties is essential to realise this
aim. To date, indocyanine green (lemB 810 nm) andmethylene
blue (lem B 700 nm) are the only two clinically-approved
near-IR fluorophores, so there is certainly much work be done
in this area.106
Quality control: the key to translation
This question of clinical translation is also pertinent in the
domain of mass spectrometry, but the technology it must first
overcome the perceived limitations with regard to quantifica-
tion before this can be fully realised.107 This is not to say that
there have not been dramatic strides made in the development
of validated analytical protocols for quantitative proteomics,108
and many manufacturers market MS products as being suitable
for such a task. Quantitative clinical proteomics must, however,
undergo rigorous validation for each individual assay, a process
that can be time consuming, expensive and complex. In 2007,
Fig. 6 Key developments in xanthene-based fluorescent sensors for Zn2+. Zinpyr-198 has been further developed to improve than range of Zn2+
concentrations it can detect (ZnAF-2F);99 measure Zn2+ flux via ratiometric measurements (ZnP1);100 localise within specific organelles, such as
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Mischak and colleagues109 presented a manifesto outlining all
areas where standards should be set for clinical proteomics to
become mainstream. Fortunately, global think tanks like the
Working Group of the International Federation of Clinical
Chemistry and Laboratory Medicine (IFCC) exist to set guidelines
for clinicians, such as their recently-released compendium of
quality indicators designed to detect pre-analytical errors (that is,
extra-laboratory influences impacting sample quality) before a
single sample is analysed.110
Like any analytical method, validation of an assay intended for
use in a clinical setting must follow the defined steps to ensure
results and their interpretation are true. Green111 described these
steps, to be performed in sequential order, as:
 Establishment of minimum criteria, where the requirements
for accuracy and precision are defined. This can be approached
on a case-by-case basis, though for diagnostic tests this is of
critical importance.
 Demonstration specificity, where the response of the
intended analyte is proven to be independent of any other inter-
fering species.
 Demonstration of linearity, where not only are five levels
of standards required for quantitative analysis, they must also
bracket the expected concentration of the analyte.
 Demonstration of accuracy, where assay of standard reference
materials is used to ensure analytical specificity and accurate
quantification.
 Determination of the range, where the acceptable window of
concentrations that adhere to the above steps is determined.
 Widening the scope by testing diﬀerent parameters to
demonstrate method suitability and reproducibility in other
laboratories.
 Establishing the limits of detection and quantification, where
the typical 3s and 10s criteria are used to assess sensitivity. In
addition, the method quantitation limit, which accounts for all
potential sources of error, from sample receipt to interpretation
of final results.
 Establishing stability to ensure consistent results are reported
over time.
 Assessing robustness, where small changes to experimental
conditions are tested to assess if analytical validity is maintained.
Though this provides a useful guide, there is no international
standard for method validation in clinical chemistry. Instead, the
guidelines set in the ‘FDA Guidance for Industry – Bioanalytical
Method Validation’112 used in the USA are the current bench-
mark worldwide. One significant limitation is the lack of
appropriate standard reference materials, a key component to
complete method validation. Well characterised mixtures of
protein standards are available,113 though these encompass
only a fraction of the human proteome. These materials are still
particularly useful in method development studies and are
supplemented by the freely-accessible and growing databases,
such as the Human Proteome Organisation’s Plasma Proteome
Project, which was a multi-laboratory endeavor to fully char-
acterise a pooled plasma sample.114 Additionally, this project
highlights the importance of standardised analytical methods,
from sample preparation though to analysis and examination
of data, in ensuring reproducibility between sites. Theodorsson’s115
extensive overview of method validation in clinical chemistry cites
the analytical rigor to which the pharmaceutical industry is sub-
jected as being the major driver of analytical validity in the clinical
laboratory. International standards, such as ISO/IEC 17025
(General requirements for the competence of testing and calibra-
tion laboratories) and ISO 15189 (Medical laboratories—Particular
requirements for quality and competence), provide laboratories
with accreditation that ensures a standard of measurement is
maintained.
However, better understanding of biochemistry highlights
some concerns with many commonly used clinical tests. For
instance, the established method used for assessing both
ceruloplasmin and non-ceruloplasmin bound copper in serum
uses a simple mathematical formula based on the assumption
that ceruloplasmin is the sole copper-binding species. This was
recently revisited by Twomey et al.,116 who found that con-
founding factors, such as copper non-specifically finding to
other serum proteins, could result in incorrect interpretation of
results. Similarly, use of LC-ICP-MS has been used to show that
traditional immunoturbidity methods used for assessing trans-
ferrin saturation with iron are also limited by similar eﬀects
and are not sensitive to small variation.117 We raise the ques-
tion that some established biochemical assays currently in use
in the pathology laboratory could be revisited with the intent of
improving analytical validity. Additionally, it is important to
understand that the diversity of tissue types found in the
human body may preclude an existing clinical test from provid-
ing truly accurate results, which in turn may require extensive
re-validation, or at least confirmation against an appropriate
matrix-matched standard.
Sample preparation is also key to ensuring analytically valid
results are obtained. This step in the analytical workflow has
been, and remains, the most significant window for the introduc-
tion of error through sample loss and contamination. Significant
eﬀort has been made to reduce possibility of human error by
integrating previously arduous tasks into automated workflows,
employing robotics for typical sample extraction, preconcentra-
tion and analysis.118 Such approaches have a vibrant future in
translation to the clinical, where robust and reproducible
analytical workflows, from sample receipt to data analysis,
are critical for standardised and transferable methods. The
development of new analytical methods, such as those used in
‘omics’ sciences has also driven further refinement of existing
sample preparation strategies,119 as well as providing opportu-
nities for innovative new approaches (e.g. nanotechnology120).
Additionally, manual handling of samples increases risk of
exposure to both hazardous biological and chemical materials.
Gałuszka et al.121 recently introduced 12 key principles of ‘green’
analytical chemistry, with the intent to reduce risks and hazards,
in addition to minimising the environmental impact of waste
products and excessive energy use.
Validation of analytical methods for the clinic is still ongoing,
and will continue to do so as new strategies begin the long path
of translational science. Through to 2009, the US Food and Drug
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plasma-based proteins, accounting for barely 1% of the human
proteome.122 Liotta et al.123 speculated in 2003 that the future
of blood-based proteomics was the integration of ‘‘new technol-
ogy created at the intersection of the fields of artificial intelligence,
nanotechnology and proteomics’’ to ‘‘provide ‘nanoharvesting’
agents designed specifically to capture and amplify classes of [low
molecular weight] biomarkers’’; though in 2016 such a resource
still seems some distance away. This is not to say, however, that
progress is not being made. With the advent of technology that
can identify small variations in incredibly complex mixtures,
like the human proteome, comes challenges for biomarker
validation. Rifai and colleagues124 noted that the biggest barrier
for the translation of biomarkers discovered through proteomics
is a misalignment between marker discovery and traditional
analytical method validation. Petricoin et al.’s125 comprehensive
2002 vision for translating proteomics from ‘‘benchside promise
into bedside reality’’ highlights how far the field has to come
before what analytical chemists may consider routine assays
in the academic world are realised in not only the medical
research field, but also in the diagnosis and treatment of
disease, though we optimistically predict that narrowing the
gap between the two disciplines will see significant advances
made in the next decade.
A vision for the future
A challenge in the translation of chemical techniques in the
biosciences is to ensure that the most promising and valuable
newly developed protocols are recognised and adopted by bio-
logical researchers. In order to ensure that both new technologies
and reagents reach mainstream research use, there is a need for
dissemination of these oﬀerings, which is best achieved through
commercialisation. Without such progress, chemical research
activity will continue fruitlessly for many years without any
contribution to biological studies. For example, time-gated
luminescence microscopy has, for a number of years, promised
to enable completely background-free imaging.126 In this
field, much chemical research has focussed on development of
luminescent probes (typically organometallic transition metal127,128
or lanthanoid complexes129,130) with long luminescence lifetimes,
but in this field, subsequent biological studies are primarily
employed using conventional (non-gated) fluorescence or confocal
microscopy. Notable exceptions arise from research groups that
have built their own time-gatedmicroscopes,131,132 but no research
has crossed from development to application stage. However,
with recent involvement of industry in the provision of parts to
build such microscopes,133 there may be greater uptake of such
technology in the future.
It is clear, therefore, that the development of reagents (such
as fluorescent probes) for bioanalysis should focus most atten-
tion on existing and embedded technologies. At the same time,
however, it is essential that such research keep abreast of
advances in the available and widely used technologies. For
example, confocal microscopes have superseded fluorescence
microscopes in the majority of research institutes, and current
confocal microscopes oﬀer very high sensitivity. As a result,
quantum yields as low as 1% can be routinely imaged very clearly,
with even lower values accessible through more sophisticated
techniques.134 Amongst chemists developing fluorescent probes,
however, the mantra persists that quantum yields must be 10%
or higher,135 an artefact of requirements of early fluorescence
microscopes. Furthermore, there have been exciting advances in
microscope technology: linear unmixing protocols enable separa-
tion of two concurrently-used fluorophores with similar emission
colours,136 while time-resolved microscopes oﬀer an additional
dimension for the development of sensors, which remains largely
unexploited.137
The challenge of widespread adoption of analytical methods
for the biosciences is particularly clear in the provision of
reagents, such as fluorescent sensors. Primarily due to a pre-
ference for a tried-and-true method over a novel technique, bio-
logical researchers will tend to use a well-established reagent,
rather than a novel chemical that has not seen widespread use,
despite any evident advantages. This is well illustrated in the
use of calcein, and its cell permeable profluorescent analogue,
calcein AM, to study the labile iron pool. Calcein was first
reported as a sensor of calcium,138 and subsequently for use in
cell viability assays,139 but since it was first reported as a sensor
of iron in 1995,140 the use of calcein AM as a measure of iron
levels has been reported countless times. Given its other appli-
cations, the probe clearly lacks selectivity, responding in fact to
all transition metals. Furthermore, it operates in a turn-oﬀ
fashion, whereby the presence of iron is signalled by a quenching
of fluorescence. This means that in live cell imaging studies, the
absence of probe is indistinguishable from the presence of iron.
The commonly used workaround, involving subsequent addition
of an iron chelator to determine the amount of probe, is an
endpoint protocol, precluding use in temporal studies of cells.
However, despite these drawbacks, and a number of elegant
fluorescent iron sensors that are selective for iron and operate
by turn-on fluorescence changes,141,142 calcein AM remains the
reagent of choice for biological studies.
Poor utilisation of new reagents in biological studies is
painfully clear more broadly in the field of probe development.
While the field of probe design is prolific, there is a lack of
translation from chemist to biologist. We recently conducted a
survey of the fluorescent sensors for intracellular Cu(I),143 and
found that of the eleven small molecule probes with demon-
strated biological utility, only two had been used in subsequent
investigations of copper biology, by the original authors or others,
and only one had been used more than once. The outliers in this
set are the copper sensor probes CS1144 and CS3145 from the
Chang group. CS1 has been used in seven subsequent studies in
systems ranging from bacteria to Alzheimer’s models,146–152
while CS3 has been used in two studies.153,154 As for new
technologies, lack of commercial availability for reagents is
certainly a factor; in fact, the authors of one study of copper in
neuroblastoma noted the lack of any commercial selective
copper sensor as the reason for their choice of non-selective,
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Much like standardisation is needed for translational to the
clinic, the push for researchers to develop new and innovative
analytical methods results in highly specialised and often
unachievable in alternative laboratories in the immediate period
following publication. Take, for example, the impressive protocol
for highly multiplexed imaging of breast tumour sections
described by Giesen et al.156 Here, the authors made use of
the CyTOF,157 a heavily modified ICP-MS using a time-of-flight
mass analyser for simultaneous detection of transient signals,
which is beyond the capacity of the sequential quadrupole-based
analyser in 95+% of ICP-MS systems installed worldwide.47
Marketed as a ‘mass cytometer’,158 the CyTOF uses prepared
reagent kits employing monoisotopic lanthanide markers for
labelling proteins and biomolecules, which can then be analysed
in solution and undergo sophisticated multivariate statistical
analysis.159 First commercialised in 2009 and now in its third
generation design, uptake of the CyTOF in the biosciences
(29 papers recorded in PubMed to 2015) is a good example of
an analytical technique designed specifically with biological
applications in mind. Charlotte Giesen’s impressive report took
this idea even further, partnering herself and Detlef Gu¨nther,
two independently noteworthy names in the analytical sciences,
with leading cancer researchers to apply laser ablation imaging
protocols to the CyTOF system with a pertinent biological
question to answer. No longer restricted by the fluorescence
cross-talk experienced using traditional microscopy, and with
ground-breaking ablation cell design mentioned previously
(see Wang et al.95), the team managed to simultaneously image
32 proteins and protein modifications at subcellular (1 mm)
resolution. As the CyTOF is mass-dependent, expression levels
of the labelled proteins could be deduced from signal intensity,
allowing multivariate ‘SPADE’ (see Qiu et al.160) analysis to
identify heterogeneity of major proteins in a set of 22 tumour
samples. As revolutionary as this example is, and it certainly
has much potential in a range of chronic disease scenarios, no
further papers have since used this technology, and the release
of a commercialised system (first alluded to by the CyTOF
manufacturer Fluidigm in mid-2014161) was still ‘‘. . .in the near
future’’ one year later.162
Duplication of methods from system to system is no more
apparent than in the most expensive category of analytical
technology: the synchrotron. There are around 40 operational
facilities worldwide, ranging in energy output significantly
depending on the design. The three ‘third generation’ synchrotrons
(Advanced Photon Source in the USA; the European Synchrotron
Radiation Facility in France, and SPring-8 in Japan) dwarf the
others in terms of size and energy capacity; all three have storage
rings able to maintain electrons at 46 GeV. This does not,
however, mean other facilities are inferior to their larger cousins—
rather, new facilities are often designed in consultation with users
and the requirements of the research environment within which
they are situated. Consequently, and even though the relatively
small size of the synchrotron research community makes it one of
the most collaborative, there are significant diﬀerences in design
and capabilities from facility to facility. Though we discuss XFM
here as a main example, it is important to recognise that imaging
metals is just one capability of a synchrotron; the newly commis-
sioned National Synchrotron Light Source (NSLS) 2 at Brookhaven
National Laboratories in the USA will eventually house over
60 beamlines, each with its own unique purpose.
As we previously discussed in our Tutorial Review on the
subject,86 detection of analytes by XFM is as reliant on the
detector as it is the sample. Many beamlines employ highly
sensitive silicon drift detectors, which have the advantage of
providing very low limits of detection and are commercially
available but are limited by slow detector overheads; whilst others,
such as the Australian Synchrotron, PETRA in Germany and the
NSLS2 have opted to use fast-scanning capabilities of the multi-
channel Maia detector,163 which sacrifices some of the advantages
of drift detectors for the benefit of high throughput analysis. Thus,
translating an experiment performed on the Maia to a beamline
where the detector not only operates in a diﬀerent manner, but
may also be positioned in a diﬀerent geometry, requires close
consultation with beamline support scientists. Fortunately, as
mentioned above, the close working relationship between synchro-
tron scientists worldwide, often through necessity, is a microcosm
of the collaborative environment we envisage will become com-
monplace in the future as analytical chemists and biologists
further recognise the benefits of applied research.
Improving communication is just one step, and sometimes
just making biomedical researchers aware of new advances in
analytical sciences can be a challenge. Giesen et al.’s156 ground-
breaking work using LA-CyTOF technology was visible to the
broader research community through publication in a leading
biotechnology journal, yet it was made possible through years
of work by scientists preceding them in the field of method
development. Unfortunately, resources for medical and biological
researchers such as PubMed often do not index analytical devel-
opment journals, though publishers specialising in the chemical
sciences have done a good job of: (1) recognising the importance
of interface science when selecting papers to be reviewed; and
(2) having their relevant journals indexed in PubMed as soon as is
practicable. Social media also has a place in cross-disciplinary
communication: a 2007 study reported that 77% of life scientists
participate in some form of online social media,164 a number that
has undoubtedly grown since these statistics were recorded. Every
journal has an online presence, and with that comes all the
necessary social media outlets, such as Twitter. However, it is
not surprising that of the 20 top scientific personalities on Twitter
(all with professional training in their discipline, though several
have crossed from being active researchers to media entities),165
there is not one analytical chemist. Furthermore, it also dis-
appointing that no female scientist makes this list, nor are
there many who would be considered young researchers.
Concluding remarks: the analytical
chemist of the future
As young investigators looking forward to careers in this field,
it is timely to consider, then, what a chemist working in this
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field has been for chemists to work on technological or reagent
development, relatively independently of those researchers using
these tools in detailed biological studies. It is clear, however, that
this is not the way forward, and that chemists must now have a
working knowledge of the biological questions they are seeking
to probe, and ideally should have ready access to simple set-ups
to perform preliminary biological validation studies. However,
we must keep in mind that scientific progress relies on colla-
borations between experts with a depth of knowledge in one field
rather than a shallow breadth, and it is therefore also essential
analytical chemists of the future foster a diverse range of colla-
borations with various biological researchers. Collaborators will
be able to provide advice on targets to be sensed, and can test the
utility and generalisability of new tools developed.
Beyond the broad generalisations of the breadth of expertise
required, the analytical chemist of the future must strive to
answer important biological questions, rather than seeking easy
targets (the ‘low hanging fruit’ paradigm) that may have less
value in biological studies. At the same time, it is essential that
researchers are able to identify when application of developed
methods is preferable to seeking to make improvements to
technology. For the chemist, the tweaking of instruments,
protocols or reagents can be facile, and while this can facilitate
more rapid publication rates, such small changes are likely to
have little impact in the broader scientific field. In contrast, true
impact of new tools will be evident through their widespread
application, so the exercise of validating and demonstrating
the utility of a single tool in a broad range of studies will have
greater impact.
The analytical chemist of the future must also be ambitious.
The most exciting research will lie not inmeasuring analytes that
have already been well studied, but in identifying prevailing
challenges in biology for which there are no current analytical
tools available. Furthermore, an analytical chemist must be a
salesperson; promoting not only existing tools, but expertise to
develop new tools in the future to as broad an audience as
possible. It is only through cross-disciplinary discussion that the
enormous potential of analytical chemistry can be harnessed.
It is helpful for emerging researchers to identify role models,
and in this field, none is more appropriate than Roger Tsien.
Perhaps best known for sharing the Nobel Prize in Chemistry in
2008 ‘‘for the discovery and development of the green fluorescent
protein, GFP’’ (Tsien’s team first described GFP’s crystal struc-
ture in 1996166), his work and legacy has extended far beyond
this field. As an emerging investigator himself, Tsien, at the time
completing a PhD in neurophysiology in the late 1970s, used his
expertise in chemistry to identify a key challenge for the area of
neurochemistry: the ability to better visualise neuronal activity.
He identified calcium as an appropriate analyte to study,
and subsequently developed the first fluorescent sensor for
calcium.167 This work pioneered the field of small molecule
fluorescent sensors, and his innovation alone demonstrates the
profound impact of such tools: calcium sensors are now routinely
used to study neuronal activity. Over thirty years ago, Tsien was
truly ahead of his time, and he exemplifies our description of the
analytical chemist of the future, a model that is disappointingly
rare amongst the current generation of researchers. Tsien’s
development of analytical tools was spurred directly by a bio-
logical question, and having produced a tool to address this
need, he subsequently demonstrated its use in various bio-
logical studies. He also continued on, pioneering the use of
ratiometric probes that signal analytes by a change in colour
rather than intensity,168 and sensors for numerous other classes
of analytes.169–171
It is certainly an exciting time to be an analytical chemist
working towards a better understanding of the biosciences. It is
encouraging that more biological research laboratories are
actively integrating dedicated analytical chemistry development
groups into the wider research teams. These are often centred
on the concept of life sciences ‘innovative ecosystems’,172 where
conglomerations of dedicated research institutes are geo-
graphically positioned within centralised locations, such as
those found in Boston in the United States, Cambridge in the
United Kingdom and Melbourne in Australia. The concept of
innovation ecosystems, explained in the wider economic sense
by Enrico Moretti,173 has the potential to build ‘brain hubs’,
where multidisciplinary scientists are encouraged to share ideas
and promote both commercial (in the case of industry-funded
or university-sponsored innovation ecosystems) and academic
innovation. Though typically viewed as a pipeline for commer-
cialisation of research, these hubs of academic endeavour also
have the potential to produce greater cohesion between multiple
disciplines, and all the intellectual benefit that comes with it.
Though the capital investment is large, many countries are
recognising the benefits of such a model, and it is a direction
that should encourage more analytical chemists and biologists
to engage in sustained dialogue, so that both respective fields
continue to flourish in an age where innovation continues to
breed the most exciting discoveries. Though the gulf between
analytical development and application within the biosciences is
still wide, trends like these are indicative of a positive shift
towards a more unified approach to what we should all consider
a common goal: the pursuit of knowledge.
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